Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam將通過網絡直播電話會議討論2024年第一季度財務業績
Apr 18, 2024
2024 年 4 月 18 日
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.
馬薩諸塞州劍橋--(美國商業資訊)--2024年4月18日-- Alnylam 製藥公司 領先的RNAi療法公司納斯達克股票代碼：ALNY）今天宣佈，將在美國金融市場開盤前於2024年5月2日星期四公佈截至2024年3月31日的第一季度財務業績。
Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations for the future via conference call on Thursday, May 2, 2024 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BI0abdd195e81a43d9ac0c44fe9d789f86. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.
管理層將在美國東部時間2024年5月2日星期四上午 8:30 的電話會議上介紹公司的最新情況，討論2024年第一季度的業績以及對未來的預期。要訪問電話，請在線註冊 https://register.vevent.com/register/BI0abdd195e81a43d9ac0c44fe9d789f86。請與會者提前一天或在電話會議開始前至少15分鐘註冊。電話會議結束兩小時後將提供電話會議的重播，並在同一個網頁上存檔六個月。
A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.
電話會議的網絡直播將在公司網站的 “投資者” 欄目上播出 www.alnylam.com/evets。活動結束大約兩小時後，將在Alnylam網站上提供存檔的網絡直播。
About Alnylam Pharmaceuticals
關於 Alnylam 製藥
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or on Instagram.
Alnylam Pharmicals（納斯達克股票代碼：ALNY）已率先將RNA干擾（RNAi）轉化爲一類全新的創新藥物，有可能改變患有罕見和流行病但需求未得到滿足的人們的生活。基於獲得諾貝爾獎的科學，RNAi療法代表了一種強大的、經過臨床驗證的方法，可以產生變革性藥物。自 2002 年成立以來，Alnylam 一直領導 RNAI 革命 並繼續實現將科學可能性變爲現實的大膽願景。Alnylam 的商用 RNAi 治療產品是 ONPATTRO （patisiran）、AMVUTTRA （vutrisiran），GIVLAARI (givosiran)、OXLUMO (lumasiran) 和 Leqvio （inclisiran），由Alnylam的合作伙伴諾華開發和商業化。Alnylam擁有豐富的研究藥物產品線，包括多個處於後期開發階段的候選產品。Alnylam 正在執行其 “Alnylam P5x25" 該戰略旨在通過可持續的創新和卓越的財務業績爲世界各地的患者提供治療罕見病和常見疾病的變革性藥物，從而使生物技術處於領先地位。Alnylam 總部位於馬薩諸塞州劍橋。有關我們的員工、科學和管道的更多信息，請訪問 www.alnylam.com 並在 X（前身爲 Twitter）上與我們互動，網址爲 @Alnylam，開啓 領英，或者開啓 Instagram。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418150859/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
Alnylam 製藥公司
克里斯汀·里根·林登布姆
（投資者和媒體）
617-682-4340
喬什·布羅德斯基
（投資者）
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
來源：Alnylam Pharmicals, Inc.
譯文內容由第三人軟體翻譯。